Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Biomarkers in Melanoma Risk
NCT04062032Phase 2Completed
- Sponsor
- University of Utah
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of aspirin in melanoma (2 arms), sponsored by University of Utah. Primary endpoints: Change in concentration of ASA metabolites (salicylate and salicylurate) in plasma at Day 7, Change in concentration of ASA metabolites in nevus tissue at Day 7 and 2 more. Started Sep 2016; status: completed.
02
Drugs
aspirin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04062032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062032.